医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

CDISC Welcomes New Leaders to 2017 Board of Directors

2017年03月21日 AM03:58
このエントリーをはてなブックマークに追加


 

AUSTIN, Texas

The Clinical Data Interchange Standards Consortium (CDISC) today announced the addition of three new members to its Board of Directors. Mr. Dave Evans, Dr. Masanori Fukushima, and Mr. Steve Rosenberg have each begun serving a three-year term.

Dave Evans is Principal Director, Global Head of Quality Governance and Regulatory Compliance for Accenture Research and Development Services. With over 35 years’ experience in the clinical research, regulatory and healthcare industries, he is recognized industry-wide as a leading technology visionary for developing and implementing complex process and system solutions.

Masanori Fukushima, M.D., Ph.D., is a Professor Emeritus at Kyoto University and Director and Chairman of Translational Research Informatics Center (TRI), Japan. An oncologist, he has over 30 years’ experience engaging in the practice and dissemination of standard cancer treatment and reforming Japan’s medical care system. Dr. Fukushima also supervises national translational research programs conducted by the government of Japan, which led to the formation of the Academic Research Organization (ARO) Council. The CDISC Standards from the Start Course was developed at the request of the ARO Council and is now offered globally.

Steve Rosenberg is Senior Vice President and General Manager of Oracle Health Sciences. He has over 30 years’ experience in the life sciences and healthcare arenas, leading development, services, support, and consulting. Mr. Rosenberg possesses a unique ability to address and influence the changing life sciences landscape, using his deep domain understanding, customer relationships, and technology vision.

“We are very pleased to welcome these new members to the CDISC Board and are grateful for their willingness to serve,” stated Dr. Rebecca Kush, CDISC President. “Their talent, vision and dedicated service to improving clinical research processes through global standards will broaden the Board’s depth and breadth and guide CDISC into the future.”

Continuing Board members include Dr. David Hardison (Chair), ConvergeHEALTH by Deloitte; Mr. Stephen Pyke (Chair-elect), GlaxoSmithKline; Dr. Charles Cooper, Becton Dickinson; Margaret Keegan, Quintiles; Dr. Rebecca Kush, CDISC; Dr. Douglas Peddicord, Association of Clinical Research Organizations (ACRO); Joyce Sensmeier, Healthcare Information and Management Systems Society (HIMSS); John Speakman, New York University; Dr. Hiromichi Shirasawa, Merck; Névine Zariffa, AstraZeneca; Dr. Jonathan Zung, Covance.

ABOUT CDISC

CDISC is a 501(c)(3) global, non-profit organization that develops data standards to foster smarter research and enable connections to healthcare. CDISC standards allow data to speak the same language, by providing common formats for data collection, data sharing and data analyses to make the most of the valuable information offered by patients participating in research studies around the globe, enabling researchers to discover new treatments, find breakthroughs, and unlock cures. CDISC Standards are required for regulatory submissions to the U.S. FDA and Japan PMDA, are endorsed by the China CFDA, and are requested for use by the European Innovative Medicines Initiative (IMI). The suite of CDISC standards is freely available on the CDISC web site.

CDISC is funded through the generous support of over 400 member organizations from pharmaceutical, biotech, clinical research organizations, regulatory agencies, academia, and healthcare, as well as through grants, authorized CDISC Education courses, events and charitable contributions. To find out more about how to support CDISC and get involved, please visit www.cdisc.org and www.unlockcures.org.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170320006142/en/

CONTACT

CDISC
Andrea Vadakin, 316-558-0160
avadakin@cdisc.org

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Acelity Strengthens Global Commercial Leadership; Names Ramesh Subrahmanian President for International Region
  • Samsung Bioepis’ Imraldi® (Adalimumab) Recommended for Approval by European Medicines Agency
  • BionextがBiosightを市場投入:医薬品研究に革命をもたらすオンラインプラットフォーム
  • Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting
  • 2017世界移动大会-上海参展商概况